N@N

Andrew Fein Reiterated (BPMC) at Strong Buy and Held Target at $70 on, Feb 17th, 2023

Andrew Fein of HC Wainwright & Co., Reiterated "Blueprint Medicines Corporation" (BPMC) at Strong Buy and Held Target at $70 on, Feb 17th, 2023.

Andrew has made no other calls on BPMC in the last 4 months.

There are 9 other peers that have a rating on BPMC. Out of the 9 peers that are also analyzing BPMC, 5 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $50 on, Friday, January 27th, 2023
• Peter Lawson of "Barclays" Maintained at Hold with Decreased Target to $44 on, Monday, January 23rd, 2023
• Derek Archila of "Wells Fargo" Upgraded from Sell to Hold and Held Target at $41 on, Tuesday, January 3rd, 2023
• Matthew Biegler of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, November 2nd, 2022
• Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $52 on, Wednesday, November 2nd, 2022

These are the ratings of the 4 analyists that currently disagree with Andrew

---

• Reni Benjamin of "JMP Securities" Reiterated at Buy and Held Target at $114 on, Monday, February 6th, 2023
• Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $108 on, Thursday, November 3rd, 2022
• Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $106 on, Wednesday, November 2nd, 2022
• Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Decreased Target to $85 on, Wednesday, November 2nd, 2022

Contributing Sources

---